VOLUNTARY ANNOUNCEMENT: SIR-SPHERES Y-90 RESIN MICROSPHERES OBTAINED RECOMMENDATION FROM NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE (NICE); AND SIRTEX OBTAINED AN APPROVAL FROM FDA TO CONDUCT CLINICAL TRIALS ON PRIMARY LIVER CANCER

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

China Grand Pharmaceutical and Healthcare Holdings Limited

遠大醫藥健康控股有限公司*

(Incorporated in Bermuda with limited liability)

(Stock Code: 00512)

VOLUNTARY ANNOUNCEMENT

SIR-SPHERES® Y-90 RESIN MICROSPHERES OBTAINED RECOMMENDATION FROM NATIONAL INSTITUTE FOR HEALTH AND

CARE EXCELLENCE（NICE）;

AND

SIRTEX OBTAINED AN APPROVAL FROM FDA TO CONDUCT CLINICAL

TRIALS ON PRIMARY LIVER CANCER

This announcement is made by the board of directors (the "Board") of China Grand Pharmaceutical and Healthcare Holdings Limited (the "Company", together with its subsidiaries, the "Group") on a voluntary basis.

The Board is pleased to announce that the Group's associate Sirtex Medical Pty Ltd ("Sirtex") has gained two important developments recently, which once again proves the clinical efficacy and competitive advantages of the product, and aids in helping more liver cancer patients worldwide receive the treatment of SIR-Spheres® Y-90 resin microspheres.

1） SIR-Spheres® Y-90 resin microspheres obtained recommendation from

NICE

National Institute for Health and Care Excellence ("NICE") recommends the use of SIR-Spheres® Y-90 resin microspheres in the treatment of unresectable advanced hepatocellular carcinoma ("HCC") in adults. As recommended by NICE, the use of selective internal radiation therapy (SIRT) using SIR-Spheres® Y-90 resin microspheres in England and Wales will be a fully funded and reimbursed option for adult patients with HCC, on the conditions that it is used for patients with Child-Pugh grade A liver impairment when conventional transarterial therapies are inappropriate. This approval opens the potential to treat nearly 2,000 patients who would be eligible for treatment with SIR-Spheres® Y-90 resin microspheres, annually, in the UK.

NICE is an important organization of National Health Service ("NHS") in England. NICE's role is to improve outcomes for people using the NHS and other public health and social care services. NICE achieve this by producing evidence-based guidance and advice for health, public health and social care practitioners, and evaluate the clinical and economic data of medical technologies. NICE have concluded that SIR-Spheres® Y-90 resin microspheres is a cost-effective use of NHS resources and the clinical evidence demonstrated the positive impact on the quality of life and economic benefits of HCC patients.

As one of the recognized premier health technology assessment organizations in the world, NICE's recommendations are highly authoritative. More than 75% of the governments and health technology assessment agencies in the world regard NICE's recommendations as an important decision-making basis for bringing products into their own medical insurance reimbursement. SIR-Spheres® Y-90 resin microspheres obtaining recommendation from NICE is a milestone for its global medical insurance reimbursement access, which is expected to accelerate its access to medical insurance reimbursement in other emerging markets (such as Brazil), further expand its market shares, and help more liver cancer patients worldwide to receive the treatment of SIR-Spheres® Y-90 resin microspheres.

2） SIR-Spheres® Y-90 resin microspheres obtained an approval from the US

Food and Drug Administration ("FDA") to conduct clinical trials on primary liver cancer

SIR-Spheres® Y-90 resin microspheres have been approved by the FDA to conduct clinical trials on primary liver cancer in order to apply for marketing license of primary liver cancer in the United States. The clinical trial is a single arm trial and patients will be recruited in the near future.

SIR-Spheres® Y-90 resin microspheres are the only radioactive microspheres around the world approved by the FDA, which are used in selective internal radiation therapy for malignant liver tumors. The SIR-Spheres® Y-90 resin microspheres are delivered to the vasculature of liver tumor via a worldwide leading interventional technology, and then emit high doses of beta radiation to destroy tumor cells.

In August 2020, SIR-Spheres® Y-90 resin microspheres received the permission from National Medical Products Administration (NMPA) in China to apply for listing on the basis of clinical trial data abroad, and submitted the listing application for the treatment of colorectal cancer liver metastasis, which was accepted on November 25, 2020.

A number of high-quality and large-sample clinical studies on SIR-Spheres® Y-90 resin microspheres have been carried out in Europe, United States, Hong Kong and Taiwan, and the results prove that SIR-Spheres® Y-90 resin microspheres can significantly increase tumor response rate, reduce tumor burden and achieve tumor downstaging, so that patients can gain the chances to undergo surgical resection. It can also significantly prolong the progression-free survival, control tumor progression and increase the waiting time for liver transplantation. In the meantime, SIR-Spheres® Y-90 resin microspheres bring less side effects and higher quality of life for patients.

SIR-Spheres® Y-90 resin microspheres has been given to over 100,000 people in over 50 countries and regions around the world. With its remarkable clinical efficacy, it is recommended for treatment of hepatic malignant tumors by many authoritative guidelines, including National Comprehensive Cancer Network (NCCN) and European Society for Medical Oncology (ESMO). It is also covered by medical insurance in places such as the United States and Europe. In addition, it is included in the Guidelines for Diagnosis and Treatment of Primary Liver Cancer in China (2019 edition) and Chinese Guidelines for the Diagnosis and Comprehensive Treatment of Colorectal Cancer Liver Metastasis (2018 edition) with clear clinical demands delineated.

Sticking to patients-centered and innovation-driven, the Group will continue to expand its strategic planning in anti-tumor field and increase its investment in the world-class innovative products in the fields of radiopharmaceuticals and precision interventional therapy. Through cooperating with the three global leading anti-tumor pharmaceutical companies which are invested by the Group, including United Stated based OncoSec Medical Incorporated (NASDAQ:ONCS), Australia based Sirtex and Telix Pharmaceuticals Limited (ASX: TLX), the Group will continue to introduce world-class innovative products for different cancer indications in response to unmet clinical needs and enrichproduct pipeline and improve supply chain, dedicating itself into building world-leading radiopharmaceuticals platform and Immunotherapy platform integrating diagnostics and treatment. The Group adopts the strategy of "global expansion and dual-cycle operation", forming a new pattern of domestic and international cycles that synergize with each other. The Group makes full use of its domestic industrial advantages and research and development capabilities, to accelerate commercialization processes for innovative products and provide cancer patients with more advanced and diverse treatment options in the world.

Warning

The aforementioned products are still in the R&D stage and the return from commercialization are subject to many factors. Shareholders and prospective investors of the Company are advised to exercise caution when dealing in the securities of the Company.

By order of the Board

China Grand Pharmaceutical and

Healthcare Holdings Limited

Liu Chengwei

Chairman

Hong Kong, 8 March 2021

As at the date of this announcement, the Board comprises four executive directors, namely, Mr. Liu Chengwei, Mr. Hu Bo, Dr. Shao Yan and Dr. Niu Zhanqi and three independent non-executive directors, namely, Ms. So Tosi Wan, Winnie, Dr. Pei Geng and Mr. Hu Yebi.

* For identification purpose only